Drugs / ISM5939
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06724042 | Jun 2026 → Jun 2029 expected | metastatic neoplasm, neoplasm | InSilico Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISM5939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06724042 ↗ |
| Route | Oral | “ISM5939 tablets will be administered orally once daily (QD).” NCT06724042 ↗ |